{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:40:26Z","timestamp":1790322026935,"version":"4.1.0"},"publisher-location":"Cham","reference-count":97,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319782799","type":"print"},{"value":"9783319782805","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/5584_2018_149","type":"book-chapter","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T23:56:18Z","timestamp":1519862178000},"page":"67-87","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Treatment of Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1007","author":[{"given":"Adriana Mihaela","family":"Ilie\u0219iu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea Simona","family":"Hodorogea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"issue":"9","key":"149_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1053\/euhj.2000.2285","volume":"22","author":"S Adamopoulos","year":"2001","unstructured":"Adamopoulos S, Parissis J, Kroupis C et al (2001) Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur Heart J 22(9):791\u2013797","journal-title":"Eur Heart J"},{"key":"149_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehi687","volume":"27","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, Rich MW, Love TE et al (2006) Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27:178\u2013186","journal-title":"Eur Heart J"},{"issue":"23","key":"149_CR3","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23):2981\u20132997","journal-title":"JAMA"},{"key":"149_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1249\/MSS.0b013e31823cd16a","volume":"44","author":"AJ Alves","year":"2012","unstructured":"Alves AJ, Ribeiro F, Goldhammer E et al (2012) Exercise training improves diastolic function in heart failure patients. Med Sci Sports Exerc 44:776\u2013785","journal-title":"Med Sci Sports Exerc"},{"key":"149_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/heart.87.1.23","volume":"87","author":"B Andersson","year":"2002","unstructured":"Andersson B, Svealv BG, Tang MS et al (2002) Longitudinal myocardial contraction improves early during titration with metoprolol CRyXL in patients with heart failure. Heart 87:23\u201328","journal-title":"Heart"},{"issue":"7","key":"149_CR6","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/0002-9149(93)90520-M","volume":"71","author":"WS Aronow","year":"1993","unstructured":"Aronow WS, Kronzon I (1993) Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 71(7):602\u2013604","journal-title":"Am J Cardiol"},{"issue":"5","key":"149_CR7","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1161\/HYPERTENSIONAHA.111.183913","volume":"59","author":"PM Becher","year":"2012","unstructured":"Becher PM, Lindner D, Miteva K et al (2012) Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and \u03b2-receptor blockade. Hypertension 59(5):949\u2013957","journal-title":"Hypertension"},{"issue":"6","key":"149_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ejheart.2004.02.003","volume":"2004","author":"A Bergstr\u00f6m","year":"2004","unstructured":"Bergstr\u00f6m A, Andersson B, Edner M et al (2004) Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic Study (SWEDIC). Eur J Heart Fail 2004(6):453\u2013461","journal-title":"Eur J Heart Fail"},{"key":"149_CR9","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1161\/CIRCULATIONAHA.111.048520","volume":"124","author":"K Bishu","year":"2011","unstructured":"Bishu K, Hamdani N, Mohammed SF et al (2011) Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation 124:2882\u20132891","journal-title":"Circulation"},{"key":"149_CR10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","volume":"32","author":"BA Borlaug","year":"2011","unstructured":"Borlaug BA, Paulus WJ (2011) Heart failure with preserved ejection fraction: pathophysiology, diagnosis and treatment. Eur Heart J 32:670\u2013679","journal-title":"Eur Heart J"},{"key":"149_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","volume":"25","author":"CG Brilla","year":"1993","unstructured":"Brilla CG, Matsubara LS, Weber KT (1993a) Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25:563\u2013575","journal-title":"J Mol Cell Cardiol"},{"key":"149_CR12","doi-asserted-by":"publisher","first-page":"12A","DOI":"10.1016\/0002-9149(93)90239-9","volume":"71","author":"CG Brilla","year":"1993","unstructured":"Brilla CG, Matsubara LS, Weber KT (1993b) Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71:12A\u201316A","journal-title":"Am J Cardiol"},{"key":"149_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/01.RES.67.4.787","volume":"67","author":"D Chapman","year":"1990","unstructured":"Chapman D, Weber KT, Eghbali M (1990) Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res 67:787\u2013794","journal-title":"Circ Res"},{"key":"149_CR14","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel O, Lainscak M, Seferovic PM et al (2017) Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19:1574\u20131585","journal-title":"Eur J Heart Fail"},{"key":"149_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.hrthm.2005.01.016","volume":"2","author":"JA Chirinos","year":"2005","unstructured":"Chirinos JA, Castrellon A, Zambrano JP et al (2005) Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvularatrial fibrillation. Heart Rhythm 2:525\u2013529","journal-title":"Heart Rhythm"},{"key":"149_CR16","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1001\/jama.297.19.2081","volume":"297","author":"TS Church","year":"2007","unstructured":"Church TS, Earnest CP, Skinner JS et al (2007) Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. JAMA 297:2081\u20132091","journal-title":"JAMA"},{"issue":"19","key":"149_CR17","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J et al (2006) PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338\u20132345","journal-title":"Eur Heart J"},{"key":"149_CR18","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1161\/CIRCULATIONAHA.110.012781","volume":"123","author":"RT Cole","year":"2011","unstructured":"Cole RT, Kalogeropoulos AP, Georgiopoulou VV et al (2011) Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation 123:2414\u20132422","journal-title":"Circulation"},{"key":"149_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","volume":"14","author":"VM Conraads","year":"2012","unstructured":"Conraads VM, Metra M, Kamp O et al (2012) Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 14:219\u2013225","journal-title":"Eur J Heart Fail"},{"issue":"9311","key":"149_CR20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE et al (2002) LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311):995\u20131003","journal-title":"Lancet"},{"key":"149_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0197-2456(95)00065-8","volume":"17","author":"Digitalis Investigation Group","year":"1996","unstructured":"Digitalis Investigation Group (1996) Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Control Clin Trials 17:77\u201397","journal-title":"Control Clin Trials"},{"key":"149_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM199702203360801","volume":"336","author":"Digitalis Investigation Group","year":"1997","unstructured":"Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525\u2013533","journal-title":"N Engl J Med"},{"key":"149_CR23","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jacc.2011.06.054","volume":"58","author":"F Edelmann","year":"2011","unstructured":"Edelmann F, Gelbrich G, Dungen HD et al (2011) Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 58:1780\u20131791","journal-title":"J Am Coll Cardiol"},{"key":"149_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG et al (2013) Aldo-DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781\u2013791","journal-title":"JAMA"},{"key":"149_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ et al (2005) SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215\u2013225","journal-title":"Eur Heart J"},{"key":"149_CR26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/CIRCHEARTFAILURE.110.958785","volume":"3","author":"RA Gary","year":"2010","unstructured":"Gary RA, Sueta CA, Dougherty M et al (2010) Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail 3:659\u2013667","journal-title":"Circ Heart Fail"},{"key":"149_CR27","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1161\/01.CIR.84.5.2181","volume":"84","author":"M Gheorghiade","year":"1991","unstructured":"Gheorghiade M, Ferguson D (1991) Digoxin: a neurohormonal modulator in heart failure? Circulation 84:2181\u20132186","journal-title":"Circulation"},{"issue":"24","key":"149_CR28","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1161\/01.CIR.0000132482.95686.87","volume":"109","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Adams KF, Colucci WS (2004) Digoxin in the management of cardiovascular disorders. Circulation 109(24):2959\u20132964","journal-title":"Circulation"},{"key":"149_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10741-012-9323-1","volume":"18","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, Marti CN, Sabbah HN et al (2013) Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev 18:123\u2013134","journal-title":"Heart Fail Rev"},{"key":"149_CR30","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J et al (2015) Effect of Vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA 314:2251\u20132262","journal-title":"JAMA"},{"issue":"6","key":"149_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000536","volume":"2","author":"SJ Greene","year":"2013","unstructured":"Greene SJ, Gheorghiade M, Borlaug BA et al (2013) The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc 2(6):e000536","journal-title":"J Am Heart Assoc"},{"key":"149_CR32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","volume":"124","author":"M Guazzi","year":"2011","unstructured":"Guazzi M, Vicenzi M, Arena R et al (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124:164\u2013174","journal-title":"Circulation"},{"issue":"24","key":"149_CR33","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1161\/01.CIR.98.24.2709","volume":"98","author":"R Hambrecht","year":"1998","unstructured":"Hambrecht R, Fiehn E, Weigl C (1998) Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 98(24):2709\u20132715","journal-title":"Circulation"},{"issue":"23","key":"149_CR34","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1001\/jama.283.23.3095","volume":"283","author":"R Hambrecht","year":"2000","unstructured":"Hambrecht R, Gielen S, Linke A et al (2000) Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. JAMA 283(23):3095\u20133101","journal-title":"JAMA"},{"key":"149_CR35","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.jacc.2007.02.055","volume":"49","author":"MJ Haykowsky","year":"2007","unstructured":"Haykowsky MJ, Liang Y, Pechter D et al (2007) A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. J Am Coll Cardiol 49:2329\u20132336","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"149_CR36","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/clc.20897","volume":"34","author":"C Jacobshagen","year":"2011","unstructured":"Jacobshagen C, Belardinelli L, Hasenfuss G et al (2011) Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Clin Cardiol 34(7):426\u2013432","journal-title":"Clin Cardiol"},{"key":"149_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1161\/01.HYP.0000236119.96301.f2","volume":"48","author":"S Julius","year":"2006","unstructured":"Julius S, Weber MA, Kjeldsen SE et al (2006) The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial. Hypertension 48:385\u2013391","journal-title":"Hypertension"},{"key":"149_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/VHRM.S83662","volume":"12","author":"M Kanwar","year":"2016","unstructured":"Kanwar M, Walter C, Clarke M et al (2016) Targeting heart failure with preserved ejection fraction: current status and future prospects. Vasc Health Risk Manag 12:129\u2013141","journal-title":"Vasc Health Risk Manag"},{"key":"149_CR39","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D et al (2016) The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893\u20132962","journal-title":"Eur Heart J"},{"key":"149_CR40","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jacc.2013.04.033","volume":"62","author":"DW Kitzman","year":"2013","unstructured":"Kitzman DW, Brubaker PH, Herrington DM et al (2013) Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am Coll Cardiol 62:584\u2013592","journal-title":"J Am Coll Cardiol"},{"key":"149_CR41","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/eurheartj\/ehu067","volume":"35","author":"M Komajda","year":"2014","unstructured":"Komajda M, Lam CSP (2014) Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 35:1022\u20131032","journal-title":"Eur Heart J"},{"issue":"11","key":"149_CR42","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/ejhf.876","volume":"19","author":"M Komajda","year":"2017","unstructured":"Komajda M, Isnard R, Cohen-Solal A et al (2017) On behalf of the prEserveD left ventricular ejectIon fraction chronic heart failure with ivabradine studY (EDIFY) investigators (2017), effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail 19(11):1495\u20131503","journal-title":"Eur J Heart Fail"},{"key":"149_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/CIRCRESAHA.108.184408","volume":"104","author":"M Kruger","year":"2009","unstructured":"Kruger M, Kotter S, Grutzner A et al (2009) Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 104:87\u201394","journal-title":"Circ Res"},{"issue":"2","key":"149_CR44","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0735-1097(00)01108-6","volume":"37","author":"A Linke","year":"2001","unstructured":"Linke A, Schoene N, Gielen S et al (2001) Endothelial dysfunction in patients with chronic heart failure: systemic effects of lower-limb exercise training. J Am Coll Cardiol 37(2):392\u2013397","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"149_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090555","volume":"9","author":"F Liu","year":"2014","unstructured":"Liu F, Chen Y, Feng X et al (2014) Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis. PLoS One 9(3):e90555","journal-title":"PLoS One"},{"issue":"6","key":"149_CR46","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/CIRCRESAHA.111.258251","volume":"110","author":"JD Lovelock","year":"2012","unstructured":"Lovelock JD, Monasky MM, Jeong EM et al (2012) Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 110(6):841\u2013850","journal-title":"Circ Res"},{"issue":"19","key":"149_CR47","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2014.15241","volume":"312","author":"LH Lund","year":"2014","unstructured":"Lund LH, Benson L, Dahlstr\u00f6m U et al (2014) Association between use of \u03b2-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA 312(19):2008\u20132018","journal-title":"JAMA"},{"issue":"2","key":"149_CR48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2012.12.002","volume":"1","author":"LS Maier","year":"2013","unstructured":"Maier LS, Layug B, Karwatowska-Prokopczuk E et al (2013) RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail 1(2):115\u2013122","journal-title":"JACC Heart Fail"},{"issue":"18","key":"149_CR49","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","volume":"54","author":"GJ Mak","year":"2009","unstructured":"Mak GJ, Ledwidge MT, Watson CJ et al (2009) Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 54(18):1674\u20131682","journal-title":"J Am Coll Cardiol"},{"issue":"32","key":"149_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta13320","volume":"13","author":"J Mant","year":"2009","unstructured":"Mant J, Doust J, Roalfe A et al (2009) Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 13(32):1\u2013207. iii","journal-title":"Health Technol Assess"},{"key":"149_CR51","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1042\/CS20070123","volume":"113","author":"AM Marney","year":"2007","unstructured":"Marney AM, Brown NJ (2007) Aldosterone and end-organ damage. Clin Sci (Lond) 113:267\u2013278","journal-title":"Clin Sci (Lond)"},{"key":"149_CR52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0033-0620(98)80053-4","volume":"40","author":"BM Massie","year":"1998","unstructured":"Massie BM, Abdalla I (1998) Heart failure in patients with preserved left ventricular systolic function: do digitalis glycosides have a role? Prog Cardiovasc Dis 40:357\u2013369","journal-title":"Prog Cardiovasc Dis"},{"key":"149_CR53","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ et al (2008) I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456\u20132467","journal-title":"N Engl J Med"},{"key":"149_CR54","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JV McMurray","year":"2014","unstructured":"McMurray JV, Packer M, Desai AS et al (2014) for the PARADIGM-HF Investigators and Committees Angiotensin\u2013Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 371:993\u20131004","journal-title":"N Engl J Med"},{"issue":"5","key":"149_CR55","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","volume":"110","author":"PM Mottram","year":"2004","unstructured":"Mottram PM, Haluska B, Leano R et al (2004) Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110(5):558\u2013565","journal-title":"Circulation"},{"issue":"Suppl 4","key":"149_CR56","first-page":"iv1","volume":"92","author":"D Noble","year":"2006","unstructured":"Noble D, Noble PJ (2006) Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium\u2013calcium overload. Heart 92(Suppl 4):iv1\u2013iv5","journal-title":"Heart"},{"key":"149_CR57","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1093\/eurheartj\/ehs100","volume":"34","author":"M Oelze","year":"2013","unstructured":"Oelze M, Knorr M, Kr\u00f6ller-Sch\u00f6n S et al (2013) Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression. Eur Heart J 34:3206\u20133216","journal-title":"Eur Heart J"},{"issue":"10","key":"149_CR58","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/eurjhf\/hfp120","volume":"11","author":"HK Parthasarathy","year":"2009","unstructured":"Parthasarathy HK, Pieske B, Weisskopf M et al (2009) A randomized, doubleblind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. Eur J Heart Fail 11(10):980\u2013989","journal-title":"Eur J Heart Fail"},{"key":"149_CR59","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62:263\u2013271","journal-title":"J Am Coll Cardiol"},{"key":"149_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF et al (2015) Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131:34\u201342","journal-title":"Circulation"},{"key":"149_CR61","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ejhf.135","volume":"16","author":"B Pieske","year":"2014","unstructured":"Pieske B, Butler J, Filippatos G et al (2014) On behalf of the SOCRATES investigators and coordinators rationale and design of the Soluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail 16:1026\u20131038","journal-title":"Eur J Heart Fail"},{"key":"149_CR62","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","volume":"38","author":"B Pieske","year":"2017","unstructured":"Pieske B, Maggioni AP, Lam CSO et al (2017) Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the Soluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J 38:1119\u20131127","journal-title":"Eur Heart J"},{"key":"149_CR63","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709\u2013717","journal-title":"N Engl J Med"},{"issue":"15","key":"149_CR64","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF et al (2014) TOPCAT investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392","journal-title":"N Engl J Med"},{"issue":"5","key":"149_CR65","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/CIRCHEARTFAILURE.112.969071","volume":"5","author":"M Redfield","year":"2012","unstructured":"Redfield M, Borlaug B, Lewis G et al (2012) Phosphodiesterase-5 inhibition in diastolic heart failure: the RELAX trial rationale and design. Circ Heart Fail 5(5):653\u2013659","journal-title":"Circ Heart Fail"},{"key":"149_CR66","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jama.2013.2024","volume":"309","author":"MM Redfield","year":"2013","unstructured":"Redfield MM, Chen HH, Borlaug BA et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309:1268\u20131277","journal-title":"JAMA"},{"issue":"10","key":"149_CR67","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/clc.4960281008","volume":"28","author":"C Roongsritong","year":"2005","unstructured":"Roongsritong C, Sutthiwan P, Bradley J et al (2005) Spironolactone improves diastolic function in the elderly. Clin Cardiol 28(10):484\u2013487","journal-title":"Clin Cardiol"},{"key":"149_CR68","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1751-7133.2012.00295.x","volume":"18","author":"NA Smart","year":"2012","unstructured":"Smart NA, Haluska B, Jeffriess L et al (2012) Exercise training in heart failure with preserved systolic function: a randomized controlled trial of the effects on cardiac function and functional capacity. Congest Heart Fail 18:295\u2013301","journal-title":"Congest Heart Fail"},{"key":"149_CR69","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0033-0620(84)90014-8","volume":"26","author":"TW Smith","year":"1984","unstructured":"Smith TW, Antman EM, Friedman PL et al (1984) Digitalis glycosides: mechanisms and manifestations of toxicity: Part I. Prog Cardiovasc Dis 26:495\u2013453","journal-title":"Prog Cardiovasc Dis"},{"issue":"9851","key":"149_CR70","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"S Solomon","year":"2012","unstructured":"Solomon S, Zile M, Pieske B et al (2012) For the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380(9851):1381\u20131395","journal-title":"Lancet"},{"issue":"5","key":"149_CR71","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Lewis EF et al (2016) TOPCAT investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37(5):455\u2013462","journal-title":"Eur Heart J"},{"key":"149_CR72","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","volume":"123","author":"JP Stasch","year":"2011","unstructured":"Stasch JP, Pacher P, Evgenov OV (2011) Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123:2263\u20132273","journal-title":"Circulation"},{"key":"149_CR73","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/01.CIR.78.3.506","volume":"78","author":"MJ Sullivan","year":"1988","unstructured":"Sullivan MJ, Higginbotham MB, Cobb FR (1988) Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects. Circulation 78:506\u2013515","journal-title":"Circulation"},{"key":"149_CR74","first-page":"219","volume-title":"Focus on cardiovascular diseases: chronic heart failure","author":"S Sundaram","year":"2002","unstructured":"Sundaram S, Zampino M, Gheorghiade M (2002) Is there still a place for digoxin in heart failure? In: van Veldhuisen DJ, Pitt B (eds) Focus on cardiovascular diseases: chronic heart failure. Benecke NI, Amsterdam, pp 219\u2013254"},{"key":"149_CR75","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"The SPRINT Research Group A Randomized Trial of Intensive versus Standard Blood-Pressure Control","year":"2015","unstructured":"The SPRINT Research Group A Randomized Trial of Intensive versus Standard Blood-Pressure Control (2015) N Engl J Med 373:2103\u20132116","journal-title":"N Engl J Med"},{"key":"149_CR76","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","year":"2016","unstructured":"The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129\u20132200","journal-title":"Eur Heart J"},{"issue":"28","key":"149_CR77","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","year":"2013","unstructured":"The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2013) 2013 ESH\/ESC guidelines for the management of arterial hypertension. Eur Heart J 34(28):2159\u20132219","journal-title":"Eur Heart J"},{"key":"149_CR78","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1152\/ajplegacy.1972.222.6.1398","volume":"222","author":"J Torretti","year":"1972","unstructured":"Torretti J, Hendler E, Weinstein E et al (1972) Functional significance of Na- K-ATPase in the kidney: effects of ouabain inhibition. Am J Phys 222:1398\u20131405","journal-title":"Am J Phys"},{"key":"149_CR79","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1161\/CIRCULATIONAHA.105.587519","volume":"113","author":"L Heerebeek van","year":"2006","unstructured":"van Heerebeek L, Borbely A, Niessen HW et al (2006) Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113:1966\u20131973","journal-title":"Circulation"},{"key":"149_CR80","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1161\/01.CIR.103.20.2441","volume":"103","author":"TR Wallhaus","year":"2001","unstructured":"Wallhaus TR, Taylor M, DeGrado TR et al (2001) Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 103:2441\u20132446","journal-title":"Circulation"},{"issue":"6","key":"149_CR81","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1161\/01.CIR.81.6.1959","volume":"81","author":"W Wang","year":"1990","unstructured":"Wang W, Chen JS, Zucker IH (1990) Carotid sinus baroreceptor sensitivity in experimental heart failure. Circulation 81(6):1959\u20131966","journal-title":"Circulation"},{"issue":"6","key":"149_CR82","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/S0735-1097(99)00048-0","volume":"33","author":"JG Warner Jr","year":"1999","unstructured":"Warner JG Jr, Metzger DC, Kitzman DW et al (1999) Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 33(6):1567\u20131572","journal-title":"J Am Coll Cardiol"},{"key":"149_CR83","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/0735-1097(89)90360-4","volume":"13","author":"KT Weber","year":"1989","unstructured":"Weber KT (1989) Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13:1637\u20131652","journal-title":"J Am Coll Cardiol"},{"key":"149_CR84","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMra000050","volume":"345","author":"KT Weber","year":"2001","unstructured":"Weber KT (2001) Aldosterone in congestive heart failure. N Engl J Med 345:1689\u20131697","journal-title":"N Engl J Med"},{"key":"149_CR85","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","volume":"83","author":"KT Weber","year":"1991","unstructured":"Weber KT, Brilla CG (1991) Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83:1849\u20131865","journal-title":"Circulation"},{"key":"149_CR86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0735-1097(92)90130-F","volume":"20","author":"KT Weber","year":"1992","unstructured":"Weber KT, Anversa P, Armstrong PW et al (1992) Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 20:3\u201316","journal-title":"J Am Coll Cardiol"},{"key":"149_CR87","doi-asserted-by":"crossref","unstructured":"Whelton PK, Carey RM, Aronow WS et al (2017) ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 201 pii: S0735-1097(17)41519-1)","DOI":"10.22141\/2307-1257.7.1.2018.122220"},{"issue":"1","key":"149_CR88","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","volume":"15","author":"K Yamamoto","year":"2013","unstructured":"Yamamoto K, Origasa H, Hori M (2013) Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15(1):110\u2013118","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"149_CR89","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1253\/circj.CJ-17-0240","volume":"81","author":"M Yamamoto","year":"2017","unstructured":"Yamamoto M, Seo Y, Ishizu T et al (2017) Effect of dipeptidyl peptidase-4 inhibitors on cardiovascular outcome and cardiac function in patients with diabetes and heart failure \u2013 insights from the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry. Circ J 81(11):1662\u20131669","journal-title":"Circ J"},{"issue":"16","key":"149_CR90","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B et al (2013) American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147\u2013e239","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"149_CR91","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B et al (2017a) ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure. Circulation 136(6):e137\u2013e161","journal-title":"Circulation"},{"key":"149_CR92","doi-asserted-by":"publisher","first-page":"e000","DOI":"10.1161\/CIR.0000000000000509","volume":"000","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B et al (2017b) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 000:e000\u2013e000. https:\/\/doi.org\/10.1161\/CIR.0000000000000509","journal-title":"Circulation"},{"issue":"9386","key":"149_CR93","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K et al (2003) CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777\u2013781","journal-title":"Lancet"},{"issue":"1","key":"149_CR94","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1161\/CIRCHEARTFAILURE.114.001598","volume":"8","author":"R Zakeri","year":"2015","unstructured":"Zakeri R, Levine JA, Koepp G et al (2015) Nitrate\u2019s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT-HFpEF) Trial: rationale and design. Circ Heart Fail 8(1):221\u2013228","journal-title":"Circ Heart Fail"},{"key":"149_CR95","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, Mc Murray JJV, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11\u201321","journal-title":"N Engl J Med"},{"issue":"5","key":"149_CR96","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","volume":"104","author":"Sean Lee Zheng","year":"2017","unstructured":"Zheng SL, Chan FT, Nabeebaccus AA et al (2017) Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Published online first: 05 August 2017. https:\/\/doi.org\/10.1136\/heartjnl-2017-311652","journal-title":"Heart"},{"issue":"2","key":"149_CR97","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1023\/A:1025387702212","volume":"17","author":"M Zi","year":"2003","unstructured":"Zi M, Carmichael N, Lye M (2003) The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther 17(2):133\u2013139","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Advances in Experimental Medicine and Biology","Heart Failure: From Research to Clinical Practice"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2018_149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T22:27:28Z","timestamp":1570832848000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/5584_2018_149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783319782799","9783319782805"],"references-count":97,"URL":"https:\/\/doi.org\/10.1007\/5584_2018_149","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}